Other described targets include ABCG2 (breast cancer-resistance protein, BRCP1) and ABCB1 (P-glycoprotein, MDR1), which were found to be overexpressed in doxorubicin-resistant ATC cancer cells (9). This evidence concerns the gene ABCG2 and cancer.